14 P < 0.05 28 5 23 82.14 P > 0.05 Clinical stage                

    Stage I 26 11 15 57.69   26 6 20 72.92   Stage II 14 11 3 21.43 P < 0.05 14 1 13 92.86 P > 0.05 Pathological differentiation                     well differentiated 24 6 18 75.00   24 7 17 70.83   moderately or poorly differentiated 16 12 4 25.00 P < 0.05 16 0 16 100.0 P < 0.05 P values represent multiple comparisons within groups PCR results The intensity (gray level) ratios of IGFBP-5/β-actin and cFLIP/β-actin PD-332991 were determined so as to represent the expression levels of IGFBP-5 and cFLIP mRNA. Larger ratios correlated with higher levels of expression of the target gene. Expression of IGFBP-5 were highest in the CIN stage II and III groups (1.0500 ± 0.0875), which were 4.94-fold higher than the relative expression levels of the normal group (0.2124 ± 0.0795) and 2.92-fold higher than those of the CC group (0.3600 ± 0.0575). The expression level in the CC group was in turn significantly higher than that of the normal group (P < 0.05) (Fig. 1). The highest expression of cFLIP mRNA was observed in the CC group (6.8874 ± 0.6663), which was 2.26-fold higher than that of the CIN stage II and III groups (3.0426 ± 0.0819). The lowest expression level was detected in the normal group (0.0246 ± 0.0100; P < 0.05) (Fig. 2 and ALK cancer Fig. 3). Figure 1 Expression of IGFBP-5 (154 bp,

A-lanes) and β-actin (540 bp, B-lanes) mRNA. M = Marker, A1 = Normal cervical tissues group, A2-5 respectively express CIN I, II, III, and cervical squamous cell carcinoma groups. Figure 2 Expression of cFLIP (226 bp, B-lanes) and β-actin (540 bp, A-lanes) mRNA. M = Marker, B1 = Normal cervical tissues group, B2–5 respectively express CIN I, II, III and cervical squamous cell carcinoma groups. Figure 3 Immunohistochemical detection of IGFBP-5 and cFLIP in patient tissues. A, Expression of IGFBP-5 in CIN I tissue: ++(×400); B, Expression of IGFBP-5 in CIN II tissue: +++ (×400); C, Expression of cFLIP

in cervical cancer tissue: ++ (×400). D, Expression of IGFBP-5 in cervical cancer tissue: – (×200). Discussion Amrubicin Insulin-like growth factor (IGF) -I and IGF-II are important somatomedins in humans. Rather than moving freely through the blood and tissue fluids, these proteins bind to IGFBPs, mainly IGFBPs 1–6. IGFBPs inhibit the activity of IGF by tightly adhering to the ligand, though some binding proteins also activate the insulin-like growth factor [1]. Therefore, IGFBPs have recently received more recognition as potential tumor suppressors in the occurrence and development of tumors. IGFBP-5 can inhibit the proliferation of some tumor cells. It has been reported that the down-regulation of IGFBP-5 correlates with the formation of oral keratinocyte cell tumors and IGFBP-5 over-expression in renal granular-cell tumor and fibroblast cell lines [2].